The need for new standard terms stems from the challenges arising from using the advanced therapies. These challenges mean that we need other types of procurement agreements than those used to procure traditional medicines.
The challenges cover several issues, for example protection of personal data for therapies for a specific patient; more complex logistics than for ordinary medicines, and special requirements for delivery times, because the therapies may have limited shelf life. Hospital pharmacies have also faced many new challenges, so it is important to include their experiences.
The Nordic countries have all experienced that concluding agreements on advanced therapies can take a long time. Among other things, this is because the countries have not had standard terms for this type of agreement, as we have for other types of medicines. The issues have been the same for all three countries, and for this reason, we have decided to collaborate on developing such terms.
Each country will continue to develop its own national contract terms and agreements, but a Nordic exchange of experience will improve our basis for establishing more flexible agreements.
"There are many good reasons for the Nordic countries wanting to share experience with standard terms for the advanced therapies. We all hope that this will help ensure that patients have quicker access to such therapies. And we also want to ensure that our suppliers receive more equal and predictable treatment – and thereby a smoother process," said Flemming Sonne.
About Sweden: www.janusinfo.se
About Norway: www.sykehusinnkjop.no